# Harmony Biosciences Reports Record Q2 2026 Revenue, Beats Estimates, Raises CFO Transition

> news · REPORTED · 2026-08-04

Harmony Biosciences reported Q2 2026 WAKIX net revenue of $261.3 million, up 30% year over year and beating analyst estimates by approximately $8 million, while reiterating full-year 2026 revenue guidance of $1.0 to $1.04 billion; the company also named Stephen Mollichella as Interim Principal Financial Officer following a CFO departure.

About Harmony Biosciences Holdings, Inc.: Harmony Biosciences Holdings is a Nasdaq-listed pharmaceutical company focused on rare neurological diseases, commercializing WAKIX (pitolisant), a first-in-class histamine H3 receptor antagonist approved for narcolepsy, while advancing a broader CNS pipeline.

- Company: Harmony Biosciences Holdings, Inc.
- Sector: therapeutics
- Primary source: https://ir.harmonybiosciences.com/news-releases/news-release-details/harmony-biosciences-report-second-quarter-2026-financial-results

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.